Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
Sarah Cannon · Tennessee Oncology · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
130
total citations
- FWCI
- 67.17
- Percentile
- 100%
- References
- 28
Citations per year
Authors
17Topics & keywords
Topics
Keywords
- Gemcitabine
- Durvalumab
- Medicine
- Placebo
- Internal medicine
- Cancer
- Response Evaluation Criteria in Solid Tumors
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.